Bank of America has raised its price target for Apple to $325, reflecting confidence in strong iPhone sales and service revenue growth ahead of the company’s Q2 earnings. In a related move, the bank boosted Eli Lilly's target to $1,294, signaling optimism for its performance. Conversely, BofA issued an 'Underperform' rating for Qualcomm with a $145 target and downgraded AstraZeneca from Buy to Underperform, highlighting challenges in the pharmaceutical sector amidst these optimistic adjustments.
“Bank of America raised its price target on Apple (AAPL) to $325 from $320 with a Buy rating, betting the Street is underestimating near-term results driven by iPhone sales strength and Services revenue growth ahead of Q2 earnings on April 30.”
“Bank of America boosted their price objective on Apple from $320.00 to $325.00 and gave the stock a 'buy' rating in a research note on Tuesday.”
“On Monday, Bank of America raised its price target on the stock to $175 from $150, keeping a ‘Buy’ rating.”
“Analysts at Bank of America reinstated coverage of Qualcomm Inc (NASDAQ:QCOM, XETRA:QCI) on Tuesday with an ‘Underperform' rating and a $145 price target.”
“Cramer thinks so because the stock got downgraded by Bank Of America from Buy to Underperform on December 1.”
“Price-Target: 260 Rating: buy Analyst: Bank of America Merrill Lynch”
“04/14/26 | Bank of America Merrill Lynch | Maintained Buy | $325 | gut”
“Bank of America raised its price target on Eli Lilly to $1,294 and maintained a 'buy' rating, implying about 35.43% upside from the prior close.”
“Bank of America · hiked · price targets · on Seagate Technology and Western Digital”
“Bank of America · raised price target for Teva · stock · $42”
“Bank of America · upgraded · AbbVie Inc. (NYSE:ABBV) · to Buy from Neutral”
“Bank of America · lifted · the price target on AbbVie · to $234 from $226”
